Chang Yi Wang

Chang Yi Wang
Born	December 19, 1951 (1951-12-19) (age 59) Taipei; Taiwan
Residence	Cold Spring Harbor, New York; Hsin Yi District Taipei
Institutions	National Taiwan University; Rockefeller University
Known for	Synthetic peptide based immunological applications in diagnostics, vaccines and immunotherapeutics.Specific applications include HIV 1,2 EIA blood screening test, HCV EIA blood screening test, Foot and mouth disease differential diagnostic test, Foot and mouth disease vaccine in swine for serotype O, Site Specific UBITh Amyloid-β Amyloid beta Vaccine for Alzheimer disease, synthetic peptide based Allergy Vaccine targeting IgE, synthetic peptide based AIDS vaccine targeting HIV receptor, and other synhetic peptide based animal health vaccines
Spouse	Nean Hu

Chang Yi Wang (traditional Chinese: 王長怡; simplified Chinese: 王长怡), is an immunologist and astute organic chemist, best known for establishing a new platform in vaccines technology that employs designer peptides Peptide as key ingredients to be formulated into vaccines for the prevention and treatment of AIDS, HIV, Alzheimer disease, allergy and other emerging infectious diseases in both humans and animals. She is the founder of United Biomedical, Inc. (UBI) headquartered in Hauppauge NY Hauppauge, New York and its group of companies in Asia. Dr. Wang has served as Chief Scientific Officer of UBI since its inception in December, 1985, and as Chairperson and Chief Executive Officer of the UBI Group of companies from 1998-2011. Dr. Wang is the author of over 120 peer-reviewed scientific publications and the inventor of over 100 patents to date. She has given various plenary lectures in the areas of Immunology, vaccination, immunotherapeutics and infectious diseases Infectious disease in many international conferences. She also serves on the scientific review committee for "Cooperative Research Partnerships for BioDefense" and “Allergy and Immunobiology” programs funded/administered by US National Institute of Health (NIH). In 2007, the New York Intellectual Property Law Association (NYIPLA) presented Dr. Wang with the US Inventor of the Year Award.^[1]

Early life and academic education

Dr. Wang was born in Taipei, Taiwan, the home of Formosa. She attended the prestigious Taipei First Girls' High School , where she first became aware of the double helix structure of DNA which served as one of the primary motivators for her continuous lifetime pursuit of biomedical science. She majored in Chemistry at National Taiwan University where she graduated summa cum laude in 1973. Subsequently, she was the first Asian woman accepted into the graduate program at the Rockefeller University in the United States where she received a Ph.D. degree in 1979 with dual specialization in both Biochemistry and Immunology. Thereafter, she joined Memorial Sloan Kettering Cancer Center where she became the youngest faculty member, principal investigator and head of the laboratory of molecular immunology, endowed by the Arthur J. and Leslie Levine Fund, at the Memorial Sloan Kettering Cancer Center from 1979 to 1985 prior to becoming an entrepreneur founding United Biomedical, Inc in the United States and subsequently its subsidiaries in Asia.

Career in immunology and as an entrepreneur in the biomedical industry

Dr. Wang has been a pioneer in following a path with the concept of “Immunology as a secret weapon of medicine,” combined with a powerful motivation to develop medical interventions through the application of basic biomedical sciences. Her first applications and inventions in the field of immunological applications of Synthetic peptide were antibody screening immunoassays employing highly optimized synthetic viral peptide antigens. First was the development of a synthetic peptide based HIV 1 test and later an HIV 1,2 diagnostic test for blood screening, which received U.S. Food and Drug Administration approvals in 1989 and 1996, respectively. These tests were subsequently approved by WHO as suitable for worldwide use. Her other inventions in this area include synthetic peptide-based blood screening diagnostics for HTLV I/II, HCV Hepatitis C virus, which has CE certification and has been sold in the global market through Organon Teknika /Biomerieux since 1991, and the SARS Coronavirus, as well as diagnostic tests for the differentiation of infected vs. vaccinated animals for Foot and mouth disease. Since 1992, she has been encouraged by the support and guidance of Dr.James D. Watson, the co-discoverer of the double-helix structure of DNA Double helix structure in the courageous pursuit of many challenging vaccine and immunotherapeutic programs employing designer synthetic peptides Synthetic peptide. Dr. Wang's United Biomedical, Inc. also received Bill and Melinda Gates Foundation Grand Challenges Explorations grant for a new approach to an AIDS vaccine.^[2][3]

A pioneer to challenge the broad peptide claims of Chiron’s worldwide HCV patent

Dr. Wang‘s patent for diagnostic HCV Hepatitis C virus peptide epitopes was the first such patent issued in the United States for HCV Hepatitis C virus. Partnering with distributor, Organon Teknika/Biomerieux, UBI’s peptide antigen based HCV blood screening test was a success in Europe in early 90s. However, patent litigation ensued between Chiron et al and UBI et al regarding Chiron’s broadly claimed HCV Hepatitis C virus epitope patent. Six Nobel laureates were involved as expert witnesses in the UK court regarding the validity of the broadly claimed Chiron HCV epitope/peptide patent. As a result of years of litigation through Dr. Wang’s valiant effort to put forth extensive technical arguments challenging the validity of Chiron’s HCV Hepatitis C virus peptide based claims, UBI’s arguments finally prevailed in 2000 in the European Patent court European patent court presided over by the technical board to invalidate all HCV Hepatitis C virus peptide based claims, which also resulted in a change in the UK patent law regarding section 44 in that “lack of support can be used to attack the breadth of patent claims even after the patent is issued.” This eventual result freed up the valuable future information to be derived from detailed RNA or DNA sequences for the benefit of research and follow up inventions using the vast amount of genomic sequences Genomic sequence generated by the biomedical community .

A pioneer in designer peptide based vaccines and immunotherapeutics as a new class of biologicals

For the past 25 years, Dr. Wang has dedicated herself to the discovery and development of a new class of biologicals comprising Immunotherapeutics and vaccine for the therapy and prevention of chronic and infectious diseases Chronic disease , and corresponding diagnostics for monitoring treatment and control of these diseases. The resultant peptide-based biologicals act by directing the immune system, and have exceptional potential in a wide range of therapeutic Therapeutic areas.

Under her direction, a new platform technology in peptide immunogen design called “UBITh“ for the development of innovative vaccines and immunotherapeutics was established. Site Specific UBITh Amyloid-β Vaccine Amyloid beta for Alzheimer disease, AIDS, and severe Allergic Disease Allergy; and for multiple animal health applications including pet contraception, Allergy, boar taint removal Boar taint and vaccine against infections caused by Porcine circovirus, Porcine Reproductive and Respiratory Syndrome Virus and Foot and mouth disease. Validation for the UBITh vaccine technology has been demonstrated by achievement of the long-sought goal to produce a synthetic peptide vaccine Synthetic peptide for Foot and mouth disease.

First Asian woman to receive New York Intellectual Property Law Association (NYIPLA) Inventor of the Year Award

The Inventor of the Year award recognizes an individual or group who, through inventive talents, has made worthwhile contributions to society by promoting “the progress of Science and useful Arts.” Dr. Chang Yi Wang was the 2007 award recipient for her work in “UBITh Peptide Immunogens.” The inventions supporting the nomination of Dr. Wang are her synthetic peptide-based immunotherapeutics Synthetic peptide, vaccines Vaccine, and diagnostic tools.

Personal life

Dr. Wang divides her time between United States, Taiwan and China for her R&D and business development activities in biomedical applications. Her husband Nean Hu^[4] devotes his time to UBI’s subsidiaries in Shanghai, China. She has one daughter.

Selected scientific publications

1. Wang, CY, Finstad, Connie L., Walfield, Alan M., Sia Charles, Sokoll, Kenneth K., et. al. Site Specific UBITh Amyloid-β Vaccine Amyloid beta for Immunotherapy of Alzheimer's Disease Alzheimer's disease. Vaccine, 2007: 25: 3041-3052.

2. Wang, CY, Walfield, Alan M. Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. [Review Article] Vaccine 2005: 23:2049-2056.

3. Hseuh PR, Kao CL, Lee CN, Chen LK, Ho MS, Sia C, Fang XD, Lynn S, et al and Wang, CY. Highly Specific Severe acute respiratory syndrome Antibody Test for Serosurveillance. Emerg. Infect. Diseases 2004, 10:1558-1562

4. Wang, C.Y., Lynn, S., Jong, M-H., Lin, Y-L., et al. Appendix 58, Full protection in pigs against FMDV challenge following single dose of synthetic emergency vaccine. In Report of the Session of the Research Group of the Standing Technical Committee of the European Commission for the Control of Foot-and-Mouth Disease. Food and Agricultural Organization, Rome, pp. 365–375, 2004.

5. Finstad, CL, Wang, CY, Kowalski J, Zhang M, Li ML, Li XM, Xi WG, Bosland MC, Murthy KK, Walfield AM, and Zamb TJ. Synthetic luteinizing Hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to Prostate Cancer immunotheray. Vaccine 2004: 22:1300-1313

6. Wang, CY, Walfield AM, Fang X, Hammerberg B, Ye J, Li ML, Shen F, Shen M, Alexander V and MacGlashan DW. Synthetic IgE peptide vaccine for immunotherapy for Allergy. Vaccine 2003, 21:1580-1590.

7. Wang, CY, Shen M, Tam G, Fang XD, Ye J, Shen F, Walfield AM, Wang JJG, et al. Synthetic AIDS vaccine by targeting HIV receptor. Vaccine 2002, 21: 89-97.

8. Wang, CY, Chang TY, Walfield AM, Ye J, Shen M, Chen SP, Li MC, Lin YL, et al. Effective Synthetic peptide vaccine for Foot and mouth disease in swine. Vaccine. 2002, 20:2603-2610.

9. Wang, CY, Chang TY, Walfield AM, Ye J, Shen M, Zhang ML, Lubroth J, et al. Synthetic Peptide-based Vaccine and Diagnostic System for Effective Control of Foot and mouth disease. Biologicals 2001, 29: 221-228.

10. Wang, CY, Sawyer LSW, Murthy KK, Fang XD, Walfield AM, et al. Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proc. Natl. Acad. Sci. United States 1999; 96:10367-10372

11. Shen F, Chen PD, Walfield AM, Ye J, House J, Brown F, Wang CY. Differentiation of convalescent animals from those vaccinated against Foot and mouth disease by a peptide ELISA. Vaccine, 1999; 17:3039-3049.

12. Singh M, Li XM, Wang H, McGee JP, Zamb T, Koff W, Wang CY, et. al. Controlled release microparticles as a single dose diphtheria toxoid vaccine; immunogenicity in small animal models. Vaccine 1998; 16:346-352.

13. Singh M. Hio C, Qiu H, Li XM, Wang CY, et al. CTL induction using synthetic peptides delivered in emulsions – critical role of the formulation procedure. Vaccine 1997; 15:1773-1778.

14. Li D, Forrest BD, Li Z, Xue P, Hanson CV, Duan S, Cheng H, Li M, Wang CY, et al. International clinical trials of HIV vaccines: II. Phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China. Asian Pac J Allergy Immunol 1997; 15: 105-113.

15. Phanuphak P. Teeratakulpixarn S, Sarangbin S, Nookhai S, Ubolyam S, Sirivichayakul S, Leesavan A, Forrest BD, Hanson CV, Li ML, Wang, CY, et al. International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pac J Allerg Immunol 1997; 15:41-48.

16. Singh M, McGee JP, Li XM, Koff W, Zamb T, Wang CY and O’Hagan DT. Biodegradable microparticles with an entrapped branched octameric peptide as a controlled-release HIV-1 vaccine. J Pharmaceut Sci 1997; 86:1229.

17. Singh M, Li XM, McGee JP, Zamb T, Koff W, Wang CY and O’Hagan DT. Controlled release microparticles as a single dose hepatitis B vaccine; evaluation of immunogenicity in mice. Vaccine 1997; 15:475.

18. Singh M, Li XM, Wang HY, McGee JP, Zamb T, Koff W, Wang CY and O’Hagan DT. Immunogenicity and protection in small-animal models with controlled-release tetanus toxois microparticles as a single-dose vaccine. Infect and Immunity 1997; 65:1716.

19. Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY and O’Hagan D. Syntehtic peptides entrapped in microparticles can elicit cytotoxic T cell T cell activity. Vaccine 1996; 14:1523.

20. Hioe CE, Qiu H, Chen PD, Bian Z, Li ML, Li J, Singh M, Kuebler P, McGee P, O’Hagan D, Zamb T, Koff W, Allsopp C, Wang CY, et al. Comparison of adjuvant formulations for cytotoxic T cell T cell induction using synthetic peptides. Vaccine 1996: 14:412-418.

21. Quiroga JA, van Binsbergen J, Wang CY, Pardo M, Navas S, Trines C, Herrero M and Carreno V. Immunoglobulin M antibody to hepatitis C virus core antigen: Correlations with viral replication, histological activity, and liver disease Liver disease outcome. Hepatol 1995; 11:1635.

22. Prince AM, Brotman B, Inchauspe G, Pascual D. Nasoff M. Hosein B and Wang CY. Patterns and prevalence of hepatitis type C infection in post-transfusion non-A, non-B hepatitis. J Inf Dis 1993; 167: 1296-1301.

23. Sheu JC, Wang JT, Wang TH, Wang CY, et al. Prevalence of hepatitis C virul infection in a community in [Taiwan]. Detection by synthetic peptide-based assay and polymerase chain reaction. J Hepatol 1993; 17:192.

24. Wang, CY, Looney, P.J., Li, M.L., Walfield, A.M., Ye, J., Hosein, B., Tam, J.P., and Wong-Staal, F. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991; 254:285-288

25. Hosein B, Fang X and Wang CY. Anti-HCV, anti-GOR, and autoimmunity. Lancet 1992, 339:871.

26. Hosein B, Fang CT, Popvsky MA, Ye J, Zhang M and Wang, CY. Improved serodiagnosis of hepaptis C virus Hepatitis C infection with synthetic peptide antigen from capsid protein. Proc Natl Acad Sci USA. 1991; 88:3647.

27. Hosein B, Present W, Wang CY, and Fang CT. synthetic peptide-based EIAs to distinguish HTLV-I from HTLV-II infection. Transfusion 1990; 30S: 513.

28. Kao HT, Gregerson PK, Tang JC, Takahashi T, Wang CY and Silver J, Molecular analysis of HLA class genes in two DR6w-related haplotypes, DRw13 DQw1 and DRw14 DQw3. J Immunol 1989; 142: 1743.

29. Sung SSJ, Bjorndahl JM, Wang CY, Kao HT and Fu SM. Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by PMA and anti-CD3 antibody Anti-CD3 monoclonal antibody. J Exp Med 1988; 167: 937.

30. Sung SSJ, Jung LKL, Walters JA, Chen W, Wang CY, and Fu SM, Production of tumor necrosis factor/cachetin by human B cell lines and tonsillar B cells. J Exp Med 1988; 168: 1539.

31. Wang CY. Synthetic-peptide-based immunodiagnosis of retrovirus infection: current status and future prospects. In “synthetic Peptides in Biotechnology.”, Edited by A. Mizrahi, Adv. In Biotechnological Processes. 1988; 10:131.

32. Shimazaki C, Wisniewolski D, Scheinberg D, Atzpodien J, Strife A, Gulati S, Fried J,Wismienolski R, Wang CY and Clarkson B. Elimination of myeloma cells from bone marrow by using Monoclonal antibodies and magnetic immunobeads. Blood 1988: 72:1248.

33. Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY and Carter DM. Expression of HLA-DR molecules by Keratinocytes Keratinocyte and prescence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med 1986; 164: 1013.

34. Gregerson P, Shen M, Song Q, Wang CY, et al. Molecular diversity of HLA-DR4 haplotypes. Proc Natl. Acad Sci USA 1986; 83: 2642. 35. Rinnooy-Kan EA, Wright SD, Welte K and Wang CY. Fc receptors on monocytes cause OKT-3 treated lymphocytes to internalize T3 and secrete IL-2. Cell Immunol 1986; 98: 181.

36. Buskin Y, Posnett DN, Pernis B and Wang CY. A new HLA-linked T cell membrane molecule, related to the beta chain of the clonotypic receptor, is associated with T3. J Exp Med 1986; 164: 458.

37. Posnett D, Wang CY and Friedman Sm. Inherited polymorphism of the human T cell antigen receptor detected by a monoclonal antibody. Proc Natl. Acad Sci USA 1986; 83:7888.

38. Tse DB, Al-Haiden M, Pernis B, Cantor CR and Wang CY. Intracellular accumulation of T cell receptor complex molecules in a human T leukemia cell line. Science 1986; 234:748.

39. Wang JG, Steel S, Wisniewolski R and Wang CY. Detection of antibodies to HTLV-III using a synthetic peptide of 21 amino acide residues corresponding to a highly antigenic segment of gp41 envelope protein. Proc Natl Acad Sci USA 1986; 83:6159.

40. Wang CY, Bushin Y, Lane CL, McGrath H and Posnett DN. Stimulation and expansion of a human T cell subpopulation by a monoclonal antibody to T cell receptor T cell receptor molecule. Hybridoma 1986; 5:179.

41. Schwarting R, Stein H and Wang CY. monoclonal antibody S-HCL1 and S-HCL3 allow the diagnosis of hairy cell leukemia. Blood 1985; 65:974.

42. Bushkin Y, Chorney MJ, Diamante E, Lane CL, Fu SM and Wang, CY. Biochemical characteriazation of a p43,12 complex: comparison to human and murine class I molecules. Mol Immunol 1985; 22:695.

43. Schwarting R, Welte K, chiorazzi N, Ralph P, Lane CL, Long CW, and Wang, CY. Biochemical characterization and purificatoin of human B cell stimulatory factory (BSF). Eur J Immunol 1985; 15:632.

44. Wang, CY, Bushkin Y, Chen BPD, Platsoucas C and Long CW. Preparation and characterization of monoclonal antibodies directed against epitopes of Human IFN-y. Hybridoma 1984; 4:321.

45. Bushkin Y, Chorney MJ, Diamante E, Fu SM and Wang, CY. Biochemical characterization of the human T6 antigen; a comparison between T6 and murine TL. Mol. Immunol 1984; 21:821.

46. Posnett DN, Biegler RD, Bushkin Y, Fisher DE, Wang, CY, Mayer LF, Chiorazzi N and Kunkel HG. T cell anti-idiotypic antibodies reveal differences between two human leukemias. J Exp Med 1984; 160:499.

47. Posnett DN, Wang, CY, Chiorazzi N, Crow MK and Kunkel HG. An antigen characteristic of hairy cell leukemia cells is expressed on certain activated B cells. J immunol 1984; 133:1635.

48. Peng RL, Al-Katib A, Knowles DM, Lu L, Broxmeyer H, Telidjian B, C Hiao JW and Wang, CY. Preparation and characterization of monoclonal antibodies recognizing two distinct differentiation antigens Pro-Im1, Pro-Im2 on early hematopoeitic cells. Blood 1984; 64:1169.

49. Rinooy Kan EA, Platzer E, Welte K, and Wang, CY. Modulation induction of the T3 antigen by OKT3 is monocyte dependent. J Immunol 1984; 133:2979.

50. Wang, CY, Azzo W, Al-Katib A, Chiorazzi N and Knowles DM. Preparation and characterization of monoclonal antibodies recognizing three distinct differentiation antigens (BL1, BL2, and BL3) on human B lymphocytes. J Immunol 1984; 1133:684.

51. Wang, CY, Al-Katib A, Lane CL, Koziner B and Fu, SM. Induction of Leu 10 (HLA-DC/DS) antigen expression by human precurso B cell lines. J Exp Med 1983; 158:1757.

52. Rinooy Kan EA, Wang, CY, Wang LC and Evans RL. Non-covalently bonded subunits of 22KD and 28KD are rapidly internalized by T cells reacted with anti-Leu4 [now termed CD3] antibody. J Immunol 1983; 131:536.

53. Biegler RD, Risher DE, Wang, CY, Rinnooy Kan EA and Kunkel HG. Idiotype-like molecules on cells of a human T-cell leukemia leukemia. J Exp Med 1983; 158:1000.

54. Welte K, Platzer EW, Wang, CY, Rinnooy Kan EA, Moore MAS and Mertelsmann R. OKT8 [now termed CD8] antibody inhibits OKT3 [now termed CD3]-induced IL-2 production and proliferation of KT8+ cells. J Immunol 1983; 131:2356.

55. Knowles DM, Tolidgian B, Maiboe CC, Halper J, Azzo W and Wang, CY. A new human B lymphocyte surface antigen (BL2) detected by a monoclonal antibodies: Distribution of benign and malignant lymphoid cells. Blood 1983; 62:191.

56. Venuta S, Mertelsmann R, Welte K, Feldman S, Wang, CY and Moore MAS. Production and regulation of Interleukin-2 in human lymphoblastic leukemias studied with T cell monoclonal antibodies. Blood 1983; 61:781.

57. Miki Y, Kishi H, Muragachi A, Maruyama S, Kishimoto S, Yamamura Y, Wang, CY and Kishimoto T. Induction of IgG production in a human monoclonal B lymphoblastoid cell line by a B cell-specific monoclonal antibody (BL2). J Immunol 1982; 1290: 1921.

58. Welte K, Wang, CY, Mertelsmann R, Venuta S, Feldman S and Moore MAS. Purification of human Interleukin-2 to apparent homogeneity and its molecular heterogeneity. J Exp Med 1982; 156:454.

59. Shin HS, Wang, CY and Choi YS. Activation of autologous reactive helpter T lymphocytes for differentiation of human B lymphocytes. J Immunol 1981: 126:2483.

60. Wang, CY, Good RA, Ammirati P, Dymbort G and Evans RL. Identification of a p69/71 complex [now termed LEU 1 or CD5] expressed on human T cells sharing determinants with B type chronic lymphatic leukemia. J Exp Med 1980; 151: 1539.

61. Halper J, Knowles DM and Wang, CY. 1a antigen expression by human malignant lymphomas: correlation with conventional lymphoid markers. Blood 1980; 55:373.

62. Gottlieb AB, FU SM, YU DTY, Wang, CY, Halper JP and Kunkel HG. The nature of the stimulation of cell in human allogeneic and autologous MLC reaction: Role of isolated IgM-bearing B cells. J Immunol 1979; 123: 1497.

63. Wang, CY, Structural and functional characterization of surface antigen on human B lymphocyte. Ph.D. Thesis, The Rockefeller University, 1979.

64. Wang, CY, Fu SM and Kunkel HG. Isolation and immunological 65. Fu SM, Chiorazzi N, Wang, CY, Montazeri CM and Kunkel HG> 1a beacharacterization of a major surface glycoprotein (gp54 [now termed CD40] preferentially expressed on certain human B cells. J Exp Med 1979; 149:1434.

65. Fu SM, Chiorazzi N, Wang, CY, Montazeri CM and Kunkel HG> 1a bearing T cells in man. Their identification and role in the generation of allogeneic helper activity. J Exp Med 1978; 148:1423.

66. Winchester RJ, Wang, CY, Gibofsky A, Kunkel HG, Lloyd K and Old, LJ. Expression of 1a-like antigens on cultured human malignant melanoma cell lines. Proc Natl. Acad Sci. 1978; 75:6235.

67. Winchester RJ, Meyers PA, Broxmeyer HE, Wang, CY, Moore MAS and Kunkel HG. Inhibition of human erythropoietic colony formation in culture by treatment with 1a antisera. J Exp Med 1978; 148:613.

68. Halper JP, Fu SM, Wang, CY, Winchester RJ and Kunkel HG. Patterns of expression of human 1a-like antigens during the terminal stages of B cell development. J Immunol 1978; 119:1520.

69. Hoffman T, Wang, CY, Winchester RJ, Ferarrini M and Kunkel HG. Human lymphocyte bearing 1a-like antigens [now termed HLA-DK or class 1 MHC antigen]: Absence in patients with infantile Hypogammaglobulinemia. J immunol 1977; 119:1250.

70. Winchester RJ, Ross, GD, Jarowski CI, Wang, CY, Halper J and Broxmeyer HE. Expression of a 1a-like antigen on human granulocytes during early stages of differentiation. Proc Natl Acad Sci 1977; 74:4012.

Professional and honorary affiliations

• National Health Institute, United States National Institutes of Health
• National Taiwan University (Adjunct Professor)
• National Tsing Hua University (Adjunct Professor)

Public speaking

Dr. Chang Yi Wang has been invited to numerous Presentations and Plenary Lectures in recent years including:

• Hsin Chu, Taiwan- Tsis-Hua University Lecture Series: “From double Helix to efficacious vaccines through rational design” April 10, 2010

• Taipei,Taiwan Forum on Vaccine Industry Development in Taiwan , Taiwan Biotech Association: “A Reflection and New Determination: Site Directed Vaccines and Immunotherapeutics” [Plenary Lecture] July 24, 2008

• Vienna, Austria International Atomic Energy Agency (IAEA)/Food and Agriculture Organization (FAO) and Office of International des Epizooties (OIE) World Organization for Animal Health: Use Of Standards and References for Serological And Molecular Tests for Transboundary Diseases In Livestock Nov. 21-24, 2006

• Montreal, Canada 5th World Congress on Vaccines, Immunization & Immunotherapy [Plenary Lecture] Nov. 6-9, 2006

• Dubai, UAE 7th Global Vaccinology Forum on Disease Immunization and Immunotherapy: Site-Specific Peptide Vaccines for Immunotherapy and Immunization and for Veterinary Applications [Plenary Lecture] March 5–7, 2005

• Tokyo, Japan 4th World Congress on Vaccines & Immunization: Site-Specific PeptideB Vaccines for Immunotherapy and Immunization Against Chronic Diseases, Cancer, Infectious Diseases Infectious Disease, and for Veterinary Applications [Plenary Lecture], Sept. 30-Oct. 3, 2004

• Washington Washington (state), D.C. US-Taiwan Business Council, The Brookings Institute, and the Center for Strategic and International Studies Symposium on The Taiwan Taiwan Presidential Elections: “Political, Economic, & Security Implications” : Reasons to Choose Taiwan May 6, 2004

• Singapore Biomedical Asia, Partnering Seminar: UBI as a Rising Star of the Biopharmaceutical Industry Nov. 4, 2003

• San Diego, California. Days of Molecular Medicine Symposium: Immunotherapy of Infectious, Chronic Diseases and Cancer by Site-Specific Peptide Vaccines March 13–15, 2003

• Cambridge, Massachusetts. Knowledge Foundation’s International Conference on HIV Vaccines: Synthetic AIDS Vaccine by Targeting HIV Receptor June 22–23, 2003

• Tainan, Taiwan International Symposium on Agricultural Biotechnology, National Cheng Kung University National Cheng Kung University: Site Specific Synthetic Peptide Antigens and Functional Antigenics: Applications to Animal Health Dec. 13-14, 2002

• Lyon, France Foundation Merieux of International Association of Biologicals Standardization: Immunological Application of Synthetic Peptides May 9–11, 2001

• Amsterdam, Netherlands IAVI Neutralization Task Force: Immunoprophylaxis, Immunotherapy, and a Synthetic AIDS Vaccine Targeting HIV Hiv Receptors April 25, 2001

• London, England HIV Therapeutics: Searching for the Next Generation: Immunoprophylaxis, Immunotherapy, and a Synthetic AIDS Aids Vaccine Targeting HIV Receptors Feb. 28-Mar 1, 2001

• Baltimore, Maryland Meeting of the Institute of Human Virology: Postexposure Immunoprophylaxis of Primary Isolate by an Antibody to HIV Receptor Complex Sept. 15, 2000

References

1. ^ "United Biomedical, Inc. CEO Dr. Chang Yi Wang named Inventor of the Year 2007 by New York Intellectual Property Law Association". NewsRx. 2007-06-17. http://www.newsrx.com/newsletters/Medical-Patent-Week/2007-06-17/55061720077MP.html/. Retrieved 2011-08-05. 
2. ^ "United Biomedical, Inc.". Bill and Melinda Gates Foundation. http://www.gatesfoundation.org/Grants-2009/Pages/United-Biomedical-Inc-OPP1008289.aspx/. Retrieved 2011-08-05. 
3. ^ "United Biomedical, Inc. (UBI) receives Bill and Melinda Gates Foundation Grand Challenges Explorations grant for a new approach to an AIDS vaccine". UBI. 2010-10-30. http://www.unitedbiomedical.com/Press/Detail.asp?SN=42/. Retrieved 2011-08-05. 
4. ^ "Management Team". UBI. http://www.unitedbiomedical.com/Cor_Info/Default.asp/. Retrieved 2011-08-05. 

External links

• Official site
• UBI Asia official site
• UBI-Asia on The Free Library, United Biomedical, Inc. and Development Fund, Executive Yuan of the Republic of China Establish UBI-Asia as a Biopharmaceutical Joint Venture.

Persondata
Name	Wang, Chang Yi
Alternative names
Short description
Date of birth	December 19, 1951
Place of birth	Taipei
Date of death
Place of death